Li Ka-shing’s HutchMed strikes US$1.1 billion deal with unit of Japan’s Takeda to license colon cancer drug

• Japan’s Takeda Pharmaceutical will exclusively develop and manufacture fruquintinib outside mainland China, Hong Kong and Macau
• HutchMed will receive US$400 million, as well as additional payments on hitting development and sales milestones